anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To provide the titled composition containing a nontoxic salt of a fatty acid having a specific carbon number, and capable of promoting the absorption of an extremely wide variety of pharmacologically active substances through the rectum to blood. CONSTITUTION:The objective composition contains a pharmacologically permissible salt (e.g. alkali metal salt, organic base salt, etc.) of a fatty acid having a carbon number of 8-12, preferably 10-12 (e.g. caprylic acid, lauric acid, etc.) in an amount of 0.5-20%, preferably 3-10% based on the whole composition. The composition promotes the absorption of a wide variety of pharmacologically active substances, especially even a beta-lactam compound such as penicillin, cephalosporin, etc. and a polymeric peptide such as insulin, etc.
The invention relates to a food therapy preparation for preventing and treating nephropathy based on the theories of preventive treatment of disease and medicine food homology, which is characterized by comprising the effective ingredients of the following raw materials in weight ratio: 6-8 barbary wolfberry fruits, 6-8 black sesame, 4-6 raspberry, 4-5 mulberry, 6-8 gordon euryale seeds, 4-6 fructus alpiniae oxyphyllae and 1-2 fennel. The prescription of the food therapy preparation is based on the theory of preventive treatment of disease, and the food therapy preparation is prepared from a sufficient amount of effective ingredients. Although the food therapy preparation is not a medicine, the actions of the medicine can be exerted. The food therapy preparation not only can greatly limit the occurrence and the development of the nephropathy, but also can save a great amount of medical resources and investments for China simultaneously. People can conveniently and correctly select the food therapy preparation in a pertinence way according to early symptoms per se to prevent the possible occurrence of the nephropathy, and thus, the purposes of disease prevention and body building are achieved. The food therapy preparation can be directly taken according to a certain amount, and can also be eaten together with foods and drinks as an additive of the foods and the drinks.
BACKGROUND: Labia minora hypertrophy (LH) is a growing aesthetic concern, yet its etiology and local lymphatic anatomy remain unclear. This study aimed to use indocyanine green (ICG) lymphography to investigate evidence of lymphedema in LH and clarify the anatomy of lymph vessels from the labia minora.
METHODS: Thirty-five patients with LH underwent preoperative ICG lymphography of their bilateral labia minora. The study reviewed demographic, ICG imaging, and measurement data to identify the characteristics of the superficial lymphatic anatomy in the labia minora.
RESULTS: The ICG lymphography findings revealed that 97.1% of the observed patterns were linear, and 2.9% were dermal backflow patterns. Further analysis of the linear patterns revealed the presence of 3 main superficial pathways originating from the labia minora and connecting to the labia majora and clitoral hood. These pathways were identified as the superior, median, and inferior channels. Based on the observed lymphatic mapping in the labia minora, 3 types were classified: type 1 (superior and inferior channels) accounted for 75.0% (51 sides), type 2 (median and inferior channels) accounted for 8.8% (6 sides), and type 3 (superior, median, and inferior channels) accounted for 16.2% (11 sides).
CONCLUSIONS: The study demonstrates that ICG lymphography enables clear visualization of superficial lymph flow from the labia minora. It also suggests that lymphedema is not a common pathologic feature of LH. Understanding the lymphatic anatomy of the labia minora can provide valuable guidance for surgical interventions involving the female external genitalia.
BACKGROUND/OBJECTIVES: Childhood obesity rates have increased in recent years. The effectiveness of future public health interventions to reduce childhood obesity will be enhanced by a better understanding of behavioral factors that influence adiposity in children as they transition from childhood to adolescence. The purpose of this study was to examine whether initial weight status modifies the longitudinal associations of physical activity, sedentary behavior, and diet quality with changes in adiposity over time.
SUBJECTS/METHODS: A total of 658 children (45% boys) were stratified into 3 groups based on 5th grade BMI percentiles ( < 85th, 85-95th, > 95th) and followed from 5th grade to 6th and/or 7th grade. Study variables, including fat-mass-index (FMI), moderate-to-vigorous physical activity (MVPA), diet quality, and sedentary behavior, were measured at 5th, 6th, and/or 7th grades. Separate growth curve models were conducted within each weight status group to examine the associations between MVPA, sedentary behavior, diet quality and adiposity, operationalized as FMI. All models controlled for sex, maturity offset, race, and parent education.
RESULTS: Of the 658 children, 53% were classified with normal weight at baseline, 18% with overweight, and 29% with obesity. Associations between MVPA, sedentary behavior, diet quality and FMI varied within each weight status group. MVPA was negatively associated with adiposity (FMI) for all weight status groups. Diet quality and sedentary behavior were associated with adiposity only in children with obesity at baseline; neither diet quality nor sedentary behavior was associated with FMI for those with overweight.
CONCLUSIONS: MVPA was negatively associated with adiposity (FMI) in all weight status groups, suggesting that MVPA may protect against higher adiposity. Sedentary behavior and diet quality were associated with adiposity only in children with obesity at baseline; neither sedentary behavior nor diet quality was associated with FMI for children with overweight.
When in the control arm, after a baseline visit, participants will up-titrate placebo (manufactured to look identical to Levetiracetam 250mg) in one tablet steps at intervals of one week to two tablets twice daily. Participants will be maintained on placebo for four weeks and have a further full assessment at 8 weeks after being on placebo. Participants will then down-titrate placebo by one tablet every week until weaned to nil.
1. A pharmaceutical composition characterized in that it comprises glycyrrhizic acid and at least one protein having antiviral activity provided, that when said protein is a lysozyme and the composition is in form of an aqueous solution it does not contain a salt of an alkali or alkaline-earth metal. 2. A composition according to claim 1, characterized in that said protein is a lysozyme and/or a lactoferrin. 3. A composition according to claim 2, characterized in that the lysozyme is selected from the group comprising chicken lysozyme, turkey lysozyme, human lysozyme, heat-inactivated chicken lysozyme, chicken lysozyme digested with trypsin. 4. A composition according to claim 2, characterized in that lactoferrin is a human or bovine lactoferrin.
Identifying high-risk patients for developing postoperative delirium (POD) is essential for optimizing the medical field's human and financial resources through specialty-relevant geriatric assessments that can aid in establishing prehabilitation strategies. This study aims to identify geriatric screening tools to predict preoperative delirium and explore the high-risk elderly patients undergoing oral maxillofacial surgery. A comprehensive geriatric assessment encompassing 23 instruments was used to evaluate inpatients undergoing surgery under general anaesthesia, preoperatively and postoperatively. Selective intraoperative and postoperative variables were also assessed for their relation to POD occurrence. This prospective study included 90 patients (mean age 79.0 years) from August 2022 to August 2023. The POD rate in this cohort was (8.9% n = 8). The Clock-Drawing Test (CDT) was significantly associated with POD occurrence (p = 0.005). Significant associations were found between POD occurrence and operation type (p = 0.018), duration (p = 0.026), length of stay ( p = 0.002), and postoperative hemoglobin levels (p = 0.027). This study highlights the importance of comprehensive geriatric assessments in predicting POD in elderly patients. Future research should build on these findings to enhance preoperative care strategies and improve outcomes.Trial registration: German Register of Clinical Studies, DRKSID DRKS00028614.
PURPOSE: A composition for improving memory power and learning ability comprising extract from artemisia apiaceae as active ingredient is provided to control antioxidant activity and activity of acetylcholinesterase. CONSTITUTION: A composition for improving memory power and learning ability including Artemisia apiaceae extract as an active ingredient. A composition for preventing or treating cognitive disorder includes the Artemisia apiaceae extract as the active ingredient. The compositions for improving memory power, learning ability, and preventing or treating cognitive disorder have several functions as follow: suppressing activity of Acetylcholinesterase, antioxidant activity, controlling or eliminating generation of reactive oxygen species, acting as antagonist [antagonist of NMDA[N-methyl-D-aspartate] receptor. The cognitive disorder stands for dementia, formerly LDH, agnosia, amnesia, aphasia, parectropia, or delirium. A pharmaceutical composition for preventing or treating cognitive disorder includes therapeutic effective amount of composition including Artemisia apiaceae extracts and pharmaceutically allowed carrier.
The invention relates to the production and the characterization of new murine monoclonal antibodies that recognize the domain CTDL-2 (SEQ ID NO: 1) of the cell receptor DEC-205 of dendritic cells in chickens (Gallus gallus) located at the surface of dendritic cells. The selected segment defined as CTLD-2 (SEQ ID NO:1), corresponding to domain 2 similar to Type C lecithins, was successfully expressed and purified in an homogeneous manner so as to be used as an immunogenic in the generation of immune responses in BALBc mice, in order to produce hybridomas which monoclonal antibodies are useful for specifically recognizing said segment. Clones 2F2 and 4D12 were obtained as those with better demonstrated results, since they express antibodies that accurately recognize the segment CTLD-2 (SQ ID NO: 1). From this segment, four lines of hybridomas were derived, amongst which the line 2F2E8D3B6 produces antibodies with the IgG2a lambda isotype that is highly recognized by the domain CTLD-2 in in vitro tests and by the receptor DEC-205 in in vivo tests. On the other hand, the RNA of the H5N2-type avian flu virus was used to produce, in a heterologous manner, the protein Hemaglutinina H5 (SEQ ID NO: 8) of the virus, which was purified and covalently conjugated to the purified antibody of the 2F2E8D3B6 clone, where said conjugate was used for immunizing laying hens. The eggs produced by the immunized hens are useful for isolating chickens (Gallu gallus). These monoclonal antibodies may be used as carriers of any pathogenic antigen against which an effective avian (potentially pig and human) vaccination is to be obtained. As there is a similarity in the sequence of domain 2, which is similar to Lecithin, in the receptors DEC-205 of different vertebrae, the crossed recognition of the antibody 2F2E8D3B6 in human cells and pig and dog spleen was proved. The obtained results indicate that the antibody recognizes the segments CTLD-2 (SEQ ID NO: 1) of the receptor DEC-205 in hum an cells (Homo sapiens) and pig cells (Sus scrofa). However, that of dog is not recognized. This means that the antibody may potentially be used for generating pig and human vaccines. The invention also includes the pharmaceutical compositions of the conjugates for being applied in the veterinary field.
The invention discloses application of Lycium barbarum polysaccharide in preventing intestinal dysbacteriosis and related cognitive dysfunction. The cognitive disorder model is a high fat, high fructose diet (HFFD) induced behavioral disorder in mice. The content of neutral sugar of the wolfberry polysaccharide is 32.92%, the content of uronic acid is 48.2%, the content of protein is 5.04%, and the content of polyphenol is 14.5%. Experimental results in the embodiment show that the lycium barbarum polysaccharide provided by the invention has obvious improving effects on cognitive dysfunction, organism inflammation level and intestinal flora disturbance of HFFD diet-induced neuroinflammatory mice, and helps to improve blood glucose homeostasis unbalance caused by HFFD diet. The matrimony vine polysaccharide improves the cognitive dysfunction of mice mainly by reducing the relative abundance of Helicobactor, desulfovibrio, desulfovibrionaceae and Proteobacteria, and promotes the production of beneficial metabolites short chain fatty acid and lactic acid by increasing the relative abundance of Allobaculum, romboutisia and Lactobacillus, thereby playing a role in neuroprotection. The wolfberry polysaccharide provided by the invention can be used for preparing various preparations for relieving cognitive dysfunction and intestinal flora dysfunction caused by high-fat and high-fructose diet.
BACKGROUND AND AIMS: Nutrition societies recommended remote hospital nutrition care during the coronavirus disease 2019 (COVID-19) pandemic. However, the pandemic's impact on nutrition care quality is unknown. We aimed to evaluate the association between remote nutrition care during the first COVID-19 wave and the time to start and achieve the nutrition therapy (NT) goals of critically ill patients.
METHODS: A cohort study was conducted in an intensive care unit (ICU) that assisted patients with COVID-19 between May 2020 and April 2021. The remote nutrition care lasted approximately 6 months, and dietitians prescribed the nutrition care based on medical records and daily telephone contact with nurses who were in direct contact with patients. Data were retrospectively collected, patients were grouped according to the nutrition care delivered (remote or in person), and we compared the time to start NT and achieve the nutrition goals.
RESULTS: One hundred fifty-eight patients (61.5 ± 14.8 years, 57% male) were evaluated, and 54.4% received remote nutrition care. The median time to start NT was 1 (1-3) day and to achieve the nutrition goals was 4 (3-6) days for both groups. The percentage of energy and protein prescribed on day 7 of the ICU stay concerning the requirements did not differ between patients with remote and patients with in-person nutrition care [95.5% ± 20.4% × 92.1% ± 26.4% (energy) and 92.9% ± 21.9% × 86.9% ± 29.2% (protein); P > 0.05 for both analyses].
CONCLUSION: Remote nutrition care in patients critically ill with COVID-19 did not impact the time to start and achieve the NT goals.
On the day of the infusion trial, participants will report to the laboratory at 0700 h after an overnight fast. MHD patients will be studied \~24 h after their dialysis treatment. A Teflon catheter will be inserted into an antecubital vein for baseline blood sample collection (t=-180 min) after which participants receive priming doses of NaH13CO2 (2.35 µmol·kg), L-\[1-13C\]leucine (7.6 µmol·kg FFM), and L-\[ring-2H5\]phenylalanine (2.0 µmol·kg FFM). Subsequently, a continuous intravenous infusion of L-\[1-13C\]leucine (0.10 µmol·kg FFM ·min) and L-\[ring-2H5\]phenylalanine (0.05 µmol·kg-1 FFM·min) will be initiated (t=-180 min) and maintained until the end of the trial. A second Teflon catheter will be inserted into a heated dorsal hand vein of the same arm for repeated arterialized blood sampling and will remain patent by a 0.9% saline drip. In the postabsorptive state, muscle biopsies will be collected at t=-120 and -0 min of the infusion. Subsequently, participants will consume a mixed meal containing 20 grams of dietary protein and the completion of the meal will mark the start of the postprandial phase (t=0 min). An additional muscle biopsy will be collected at 300 min to determine postprandial myofibrillar protein synthesis rates. Biopsies will be collected from the middle region of the vastus lateralis (15 cm above the patella) with a Bergström needle modified for suction under local anesthesia (2% Lidocaine). The postabsorptive muscle biopsies will be collected from the same incision with the needle pointed to distal and proximal directions, respectively. The postprandial biopsy will be collected through a separate incision 2-3 cm above the postabsorptive incision. All biopsy samples will be freed from any visible blood, adipose, and connective tissue immediately frozen in liquid nitrogen, and stored at -80˚C until subsequent analysis.
The active intervention consisted of two major components: dietary counseling and physical activity. Dietary counseling was performed by trained dieticians on four separate occasions at 15, 20, 28 and 35 weeks gestation.
A topical plaster for treating rheumatism and arthralgia due to cold-dampness comprises main materials and adjuvants. The main materials of the plaster comprise eighteen Chinese medicinal decoction pieces of radix Aconiti, radix Aconiti Kusnezoffii, herba Ephedrae, ramulus Cinnamomi, radix Angelicae sinensis, herba asari, radix Clematidis, rhizoma Ligustici Chuanxiong, rhizoma corydalis, olibanum, myrrha, cortex Phellodendri, radix Dipsaci, achyranthis radix, parched semen Persicae, herba Lycopodii, scolopendra, scorpio, etc., and the auxiliary materials comprise oleum Sesami and Plumbum Preparatium. The externally applied plaster for treating rheumatism and arthralgia is mainly used for treating limb and bone arthralgia such as rheumatoid arthritis, mixed connective tissue diseases, lumbar muscle strain, tendinitis and the like, and has remarkable curative effect. The invention has flexible formula, can obviously improve the main symptoms of patients and achieves the purpose of rehabilitation. For oral administration of toxic or limited amount of Chinese medicinal decoction pieces, the dosage can be added for external use, and no toxic or side effects are caused. If the measures such as oral administration of traditional Chinese medicine, massage, acupuncture and moxibustion, exercise intervention training and the like are combined, the physical condition of a patient can be rapidly and effectively improved, and the pain of the patient can be relieved. The plaster is convenient to carry and use, thus having wide utilization space and development prospect.
1. Technical Result Prolongation of the active component effect.          2. Essence Novel forms of sustained-release microgranules (LP) containing diltiazem are disclosed. The microgranules consist of a neutral granular carrier coated with an active layer including diltiazem or a pharmaceutically acceptable salt thereof as the active principle, a surfactant and a binder, and an outer layer providing sustained release of the active principle (layer LP)          3. Field of Application Medicine.               Tables: 48
BACKGROUND: Familial chylomicronemia syndrome is a genetic disorder associated with severe hypertriglyceridemia and severe acute pancreatitis. Olezarsen reduces the plasma triglyceride level by reducing hepatic synthesis of apolipoprotein C-III.
METHODS: In a phase 3, double-blind, placebo-controlled trial, we randomly assigned patients with genetically identified familial chylomicronemia syndrome to receive olezarsen at a dose of 80 mg or 50 mg or placebo subcutaneously every 4 weeks for 49 weeks. There were two primary end points: the difference between the 80-mg olezarsen group and the placebo group in the percent change in the fasting triglyceride level from baseline to 6 months, and (to be assessed if the first was significant) the difference between the 50-mg olezarsen group and the placebo group. Secondary end points included the mean percent change from baseline in the apolipoprotein C-III level and an independently adjudicated episode of acute pancreatitis.
RESULTS: A total of 66 patients underwent randomization; 22 were assigned to the 80-mg olezarsen group, 21 to the 50-mg olezarsen group, and 23 to the placebo group. At baseline, the mean (±SD) triglyceride level among the patients was 2630±1315 mg per deciliter, and 71% had a history of acute pancreatitis within the previous 10 years. Triglyceride levels at 6 months were significantly reduced with the 80-mg dose of olezarsen as compared with placebo (-43.5 percentage points; 95% confidence interval [CI], -69.1 to -17.9; P<0.001) but not with the 50-mg dose (-22.4 percentage points; 95% CI, -47.2 to 2.5; P = 0.08). The difference in the mean percent change in the apolipoprotein C-III level from baseline to 6 months in the 80-mg group as compared with the placebo group was -73.7 percentage points (95% CI, -94.6 to -52.8) and between the 50-mg group as compared with the placebo group was -65.5 percentage points (95% CI, -82.6 to -48.3). By 53 weeks, 11 episodes of acute pancreatitis had occurred in the placebo group, and 1 episode had occurred in each olezarsen group (rate ratio [pooled olezarsen groups vs. placebo], 0.12; 95% CI, 0.02 to 0.66). Adverse events of moderate severity that were considered by a trial investigator at the site to be related to the trial drug or placebo occurred in 4 patients in the 80-mg olezarsen group.
CONCLUSIONS: In patients with familial chylomicronemia syndrome, olezarsen may represent a new therapy to reduce plasma triglyceride levels. (Funded by Ionis Pharmaceuticals; Balance ClinicalTrials.gov number, NCT04568434.).
A plant salt containing phosphatidylserine is provided. The plant salt comprises a suaeda salsa extract product, persimmon powder, lesser galangal rhizome powder, fig powder, a horse chestnutextract product, a cherry extract product, sanqi leaf total saponin and the phosphatidylserine. A preparing method of the plant salt containing the phosphatidylserine is disclosed. The method includes preparing the suaeda salsa extract product. The step of preparing the suaeda salsa extract product includes raw material crushing, enzymolysis and heavy metal removing. Beneficial effects of the plant salt and the method are that after eating the plant salt, symptoms comprising abdominal swelling and pain and dyspepsia of patients are obviously improved, the effective rate for improving the abdominal swelling and pain is 94-100%, the effective rate for improving dyspepsia is 93-98%, a long-term constipation symptom of patients is obviously improved, the effective rate for improving the long-term constipation is 94-98%, the hemorrhoid symptom of patients is obviously improved, and the effective rate for improving the hemorrhoid is 84-94%.
A timed up and go test is a test that assesses the mobility and lower extremity mobility. For this test, the patient will be asked to lift from a chair with armrest (sitting height: 46 cm), walk 3 meters as fast as possible, turn around the colored band marked on the floor and sit in the same chair. The elapsed time for the motion will be recorded in seconds.
This study is divided into two dose groups and two phases. Phase Ia climbed from low-dose group to high-dose group in turn according to the 3+3 dose escalation principle. Phase Ib extended 10 subjects each group.